Abstract
COVID-19 morbidity and mortality is increased in patients with diabetes and kidney disease via unknown mechanisms. SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) for entry into host cells. Since ACE2 is a susceptibility factor for infection, we investigated how diabetic kidney disease (DKD) and medications alter ACE2 receptor expression in kidneys. Single cell RNA profiling of healthy living donor (LD) and DKD kidney biopsies revealed ACE2 expression primarily in proximal tubular epithelial cells (PTEC). This cell specific localization was confirmed by in situ hybridization. ACE2 expression levels were unaltered by exposures to renin angiotensin aldosterone system inhibitors in DKD. Bayesian integrative analysis of a large compendium of public -omics datasets identified molecular network modules induced in ACE2-expressing PTEC in DKD (searchable at hb.flatironinstitute.org/covid-kidney) that were linked to viral entry, immune activation, endomembrane reorganization, and RNA processing. The DKD ACE2-positive PTEC module overlapped with expression patterns seen in SARS-CoV-2 infected cells. Similar cellular programs were seen in ACE2-positive PTEC obtained from urine samples of 13 COVID-19 patients who were hospitalized, suggesting a consistent ACE2-coregulated PTEC expression program that may interact with the SARS-CoV-2 infection processes. Thus SARS-CoV-2 receptor networks can seed further research into risk stratification and therapeutic strategies for COVID-19 related kidney damage.
Translational statement To understand the overwhelming burden of kidney disease in COVID-19, we mapped the expression of the SARS-CoV-2 receptor, ACE2, in healthy kidney, early diabetic (DKD) and COVID-19 associated kidney diseases. Single cell RNA sequencing of 111035 cells identified ACE2 predominantly in proximal tubular epithelial cells. ACE2 upregulation was observed in DKD, but was not associated with RAAS inhibition, arguing against an increased risk of COVID-19 among patients taking RAAS inhibitors. Molecular network analysis linked ACE2 expression to innate immune response and viral entry machinery, thereby revealing potential therapeutic strategies against COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported in part by the Intramural Research Program at the National Institute of Diabetes and Digestive and Kidney Diseases (DK069062) to HCL and RGN and (DK083912, DK082841, DK020572, DK092926) to RGK, by the extramural research program of the National Institute of Diabetes and Digestive and Kidney Diseases R24 DK082841 Integrated Systems Biology Approach to Diabetic Microvascular Complications and P30 DK081943 University of Michigan O'Brien Kidney Translational Core Center to MK, via Kidney Precision Medicine Project (KPMP, funded by the following grants from the NIDDK: U2C DK114886, UH3DK114861, UH3DK114866, UH3DK114870, UH3DK114908, UH3DK114915, UH3DK114926, UH3DK114907, UH3DK114920, UH3DK114923, UH3DK114933, and UH3DK114937, with U2C DK114886 and UH3 DK114907) to MK and OGT, via the Chan Zuckerberg Initiative Human Cell Atlas Kidney Seed Network to MK and OGT and by JDRF 5-COE-2019-861-S-B JDRF and M-Diabetes Center of Excellence at the University of Michigan to MK
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All studies of the DKD population were approved by the Institutional Review Board of the National Institute of Diabetes and Digestive under protocol 13-DK-N151. Transplant biopsies were obtained after review and approval of the Transplant Transcriptomic Atlas study under HUM00150968; DKD kidney biopsies gene expression analysis was performed under HUM00002468; COVID-19 urine samples were obtained after review and approval under HUM00004729, all reviewed by the University of Michigan IRBMED.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
LD single cell data sets are searchable at NephroCell.miktmc.org. Owing to ethical considerations, privacy protection concerns, and to avoid identifying individual study participants in vulnerable populations, the Institutional Review Board of the National Institute of Diabetes and Digestive and Kidney Diseases has stipulated that individual-level gene expression and genotype data from the American Indian DKD study cannot be made publicly available. A dynamic user-friendly interface at HumanBase (hb.flatironinstitute.org/covid-kidney) is available for researchers to explore the functional networks of gene expression signatures.